UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE

Blood advances, 2023-04, Vol.7 (8), p.1507-1512

2023

Volltextzugriff (PDF)

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Volltextzugriff (PDF)

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Future oncology (London, England), 2024-01, Vol.20 (3), p.131-143

2024

Volltextzugriff (PDF)

Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination

The Annals of pharmacotherapy, 2014-02, Vol.48 (2), p.292-296

2014

Volltextzugriff (PDF)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Clinical lymphoma, myeloma and leukemia, 2020-11, Vol.20 (11), p.e910-e925

2020

Volltextzugriff (PDF)

Creating diversity, equity, inclusion, and access in cancer clinical research: Drive rank and Drive score

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13636-e13636

2022

Volltextzugriff (PDF)

Clinical research in the community

Hematology, 2023-12, Vol.2023 (1), p.324-331

2023

Volltextzugriff (PDF)

Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma

Clinical cancer research, 2024-07, Vol.30 (14), p.2895-2904

2024

Volltextzugriff (PDF)

PB2089: IN‐CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM‐6

HemaSphere, 2023-08, Vol.7 (S3), p.e149880d-n/a

2023

Volltextzugriff (PDF)

Yttrium-90 radioembolization for breast cancer with liver metastases: A focus on mortality, adverse reactions, and radiological response

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e13065-e13065

2020

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

The lancet oncology, 2020-04, Vol.21 (4), p.519-530

2020

Volltextzugriff (PDF)

Atypical identification of Lynch syndrome by immunohistochemistry and microsatellite instability analysis on jejunal adenocarcinoma

Hereditary cancer in clinical practice, 2011-03, Vol.9 (Suppl 1), p.P27-P27

2011

Volltextzugriff (PDF)

Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer

International journal of cancer, 2023-02, Vol.152 (3), p.447-457

2023

Volltextzugriff (PDF)

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Blood, 2022-11, Vol.140 (Supplement 1), p.7322-7323

2022

Volltextzugriff (PDF)

Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation

JCO oncology practice, 2020-03, Vol.16 (3), p.137-138

2020

Volltextzugriff (PDF)

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Blood, 2021-11, Vol.138 (Supplement 1), p.2726-2726

2021

Volltextzugriff (PDF)

P-114 In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S97-S98

2023

Volltextzugriff (PDF)

Sleep Disturbance Among Individuals with Multiple Myeloma: The Interplay between Physical and Psychosocial Symptoms

Blood, 2018-11, Vol.132 (Supplement 1), p.4830-4830

2018

Volltextzugriff (PDF)

Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.4787-4787

2018

Volltextzugriff (PDF)

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Blood, 2019-11, Vol.134 (Supplement_1), p.3168-3168

2019

Volltextzugriff (PDF)

P-204: In-class transition (iCT) from parenteral bortezomib to oral ixazomib therapy in newly diagnosed multiple myeloma (NDMM) patients (pts): fully accrued data from the communitybased US MM-6 study

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S147-S148

2022

Volltextzugriff (PDF)

Severe Hypoglycemia Caused by Lenalidomide

Pharmacotherapy, 2018-01, Vol.38 (1), p.e1-e6

2018

Volltextzugriff (PDF)

MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S501-S501

2023

Volltextzugriff (PDF)

POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S221-S221

2023

Volltextzugriff (PDF)

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Blood, 2019-11, Vol.134 (Supplement_1), p.1882-1882

2019

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(39)
Berichte
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Creating diversity, equity, inclusion, and access in cancer clinical research: Drive rank and Drive score

Clinical research in the community

Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma

PB2089: IN‐CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM‐6

Yttrium-90 radioembolization for breast cancer with liver metastases: A focus on mortality, adverse reactions, and radiological response

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Atypical identification of Lynch syndrome by immunohistochemistry and microsatellite instability analysis on jejunal adenocarcinoma

Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation

P-114 In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study

Sleep Disturbance Among Individuals with Multiple Myeloma: The Interplay between Physical and Psychosocial Symptoms

Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

P-204: In-class transition (iCT) from parenteral bortezomib to oral ixazomib therapy in newly diagnosed multiple myeloma (NDMM) patients (pts): fully accrued data from the communitybased US MM-6 study

Severe Hypoglycemia Caused by Lenalidomide

MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study

POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Suchergebnisse filtern